• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Akumin Inc. (Amendment)

    7/6/23 5:16:21 PM ET
    $AKU
    Medical Specialities
    Health Care
    Get the next $AKU alert in real time by email
    SC 13D/A 1 brhc20055591_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

    Akumin Inc.
    (Name of Issuer)

    Common Stock, par value $0.01 per share
    (Title of Class of Securities)

    01021X100
    (CUSIP Number)

    Adrienne Saunders
    General Counsel
    c/o Stonepeak Infrastructure Partners
    55 Hudson Yards
    550 W. 34th St., 48th Floor
    New York, NY 10001
    212-907-5100
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    June 26, 2023
    (Date of Event which Requires Filing of this Statement)

    If the filing persons has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 2 of 13 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    STONEPEAK MAGNET HOLDINGS LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    20,614,093 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    20,614,093 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    20,614,093 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.2% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    1.
    This amount includes 17,114,093 shares of Common Stock (as defined herein) that Stonepeak Magnet Holdings LP has the right to acquire upon exercise of the Warrants.
      2.
    This percentage is based on the sum of (i) 90,498,491 shares of Common Stock outstanding as of May 8, 2023, based on the Issuer’s quarterly report on Form 10-Q, filed with the SEC (as defined herein) on May 10, 2023, plus, (ii) for purposes of calculating the Reporting Person’s beneficial ownership pursuant to Rule 13d-3(d)(i) under the Act, the 17,114,093 shares of Common Stock issuable upon exercise of the Warrants, for a total of 107,612,584 shares of Common Stock outstanding.

     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 3 of 13 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    STONEPEAK ASSOCIATES IV LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    20,614,093 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    20,614,093 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    20,614,093 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.2% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO, HC
     
     
     
     


    1.
    This amount includes 17,114,093 shares of Common Stock (as defined herein) that Stonepeak Magnet Holdings LP has the right to acquire upon exercise of the Warrants.

    2.
    This percentage is based on the sum of (i) 90,498,491 shares of Common Stock outstanding as of May 8, 2023, based on the Issuer’s quarterly report on Form 10-Q, filed with the SEC (as defined herein) on May 10, 2023, plus, (ii) for purposes of calculating the Reporting Person’s beneficial ownership pursuant to Rule 13d-3(d)(i) under the Act, the 17,114,093 shares of Common Stock issuable upon exercise of the Warrants, for a total of 107,612,584 shares of Common Stock outstanding.
     

     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 4 of 13 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    STONEPEAK GP INVESTORS IV LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    20,614,093 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    20,614,093 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    20,614,093 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.2% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO, HC
     
     
     
     


    1.
    This amount includes 17,114,093 shares of Common Stock (as defined herein) that Stonepeak Magnet Holdings LP has the right to acquire upon exercise of the Warrants.

    2.
    This percentage is based on the sum of (i) 90,498,491 shares of Common Stock outstanding as of May 8, 2023, based on the Issuer’s quarterly report on Form 10-Q, filed with the SEC (as defined herein) on May 10, 2023, plus, (ii) for purposes of calculating the Reporting Person’s beneficial ownership pursuant to Rule 13d-3(d)(i) under the Act, the 17,114,093 shares of Common Stock issuable upon exercise of the Warrants, for a total of 107,612,584 shares of Common Stock outstanding.


     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 5 of 13 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    STONEPEAK GP INVESTORS HOLDINGS LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    20,614,093 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    20,614,093 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    20,614,093 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.2% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO, HC
     
     
     
     


    1.
    This amount includes 17,114,093 shares of Common Stock (as defined herein) that Stonepeak Magnet Holdings LP has the right to acquire upon exercise of the Warrants.

    2.
    This percentage is based on the sum of (i) 90,498,491 shares of Common Stock outstanding as of May 8, 2023, based on the Issuer’s quarterly report on Form 10-Q, filed with the SEC (as defined herein) on May 10, 2023, plus, (ii) for purposes of calculating the Reporting Person’s beneficial ownership pursuant to Rule 13d-3(d)(i) under the Act, the 17,114,093 shares of Common Stock issuable upon exercise of the Warrants, for a total of 107,612,584 shares of Common Stock outstanding.

     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 6 of 13 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    STONEPEAK GP INVESTORS UPPER HOLDINGS LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    20,614,093 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    20,614,093 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    20,614,093 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.2% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO, HC
     
     
     
     


    1.
    This amount includes 17,114,093 shares of Common Stock (as defined herein) that Stonepeak Magnet Holdings LP has the right to acquire upon exercise of the Warrants.

    2.
    This percentage is based on the sum of (i) 90,498,491 shares of Common Stock outstanding as of May 8, 2023, based on the Issuer’s quarterly report on Form 10-Q, filed with the SEC (as defined herein) on May 10, 2023, plus, (ii) for purposes of calculating the Reporting Person’s beneficial ownership pursuant to Rule 13d-3(d)(i) under the Act, the 17,114,093 shares of Common Stock issuable upon exercise of the Warrants, for a total of 107,612,584 shares of Common Stock outstanding.
     


     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 7 of 13 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    STONEPEAK GP INVESTORS HOLDINGS MANAGER LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    20,614,093 (1)
     
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    20,614,093 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    20,614,093 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.2% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO, HC
     
     
     
     


    1.
    This amount includes 17,114,093 shares of Common Stock (as defined herein) that Stonepeak Magnet Holdings LP has the right to acquire upon exercise of the Warrants.

    2.
    This percentage is based on the sum of (i) 90,498,491 shares of Common Stock outstanding as of May 8, 2023, based on the Issuer’s quarterly report on Form 10-Q, filed with the SEC (as defined herein) on May 10, 2023, plus, (ii) for purposes of calculating the Reporting Person’s beneficial ownership pursuant to Rule 13d-3(d)(i) under the Act, the 17,114,093 shares of Common Stock issuable upon exercise of the Warrants, for a total of 107,612,584 shares of Common Stock outstanding.

     


     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 8 of 13 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    MICHAEL DORRELL
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    20,614,093 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    20,614,093 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    20,614,093 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.2% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN, HC
     
     
     
     


    1.
    This amount includes 17,114,093 shares of Common Stock (as defined herein) that Stonepeak Magnet Holdings LP has the right to acquire upon exercise of the Warrants.

    2.
    This percentage is based on the sum of (i) 90,498,491 shares of Common Stock outstanding as of May 8, 2023, based on the Issuer’s quarterly report on Form 10-Q, filed with the SEC (as defined herein) on May 10, 2023, plus, (ii) for purposes of calculating the Reporting Person’s beneficial ownership pursuant to Rule 13d-3(d)(i) under the Act, the 17,114,093 shares of Common Stock issuable upon exercise of the Warrants, for a total of 107,612,584 shares of Common Stock outstanding.


     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 9 of 13 Pages
    Explanatory Note: This Amendment No. 1 to the Schedule 13D (“Amendment No. 1”) is being filed by the undersigned, pursuant to §240.13d-2(a), to amend and supplement the statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on September 2, 2021 (the “Original Schedule 13D” and, together with this Amendment No. 1, the “Schedule 13D”). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D.

    Item 1.
    Security and Issuer

    Item 1 of the Original Schedule 13D is hereby amended and restated as follows:

    This Schedule 13D relates to the Common Stock, par value $0.01 (the “Common Stock”), of Akumin Inc., a corporation incorporated in Ontario, Canada (the “Issuer” or “Company”).  The Issuer’s principal executive offices are located at 8300 W. Sunrise Boulevard, Plantation, Florida 33322.

    Item 2.
    Identity and Background

    Item 2 of the Original Schedule 13D is hereby amended and restated as follows:
    (a-c, f) This Schedule 13D is filed jointly by each of the following persons (collectively, the “Reporting Persons”):


    i.
    Stonepeak Magnet Holdings LP (“Stonepeak Magnet”), a Delaware limited partnership;

    ii.
    Stonepeak Associates IV LLC, a Delaware limited liability company;

    iii.
    Stonepeak GP Investors IV LLC, a Delaware limited liability company;

    iv.
    Stonepeak GP Investors Holdings LP, a Delaware limited partnership;

    v.
    Stonepeak GP Investors Upper Holdings LP, a Delaware limited partnership;

    vi.
    Stonepeak GP Investors Holdings Manager LLC, a Delaware limited liability company; and

    vii.
    Michael Dorrell (“Mr. Dorrell”), a citizen of the United States of America.

    This Schedule 13D relates to the Common Stock and Warrants held directly by Stonepeak Magnet, an investment vehicle formed for the primary purpose of making this specific investment. Stonepeak Associates IV LLC is the sole general partner of Stonepeak Magnet.  Stonepeak GP Investors IV LLC is the sole member of Stonepeak Associates IV LLC.  Stonepeak GP Investors Holdings LP is the managing member of Stonepeak GP Investors IV LLC. Stonepeak GP Investors Upper Holdings LP is the general partner of Stonepeak GP Investors Holdings LP.  Stonepeak GP Investors Holdings Manager LLC is the general partner of Stonepeak GP Investors Upper Holdings LP.  Mr. Michael B. Dorrell is the Chairman, Chief Executive Officer, co-founder and sole member of Stonepeak GP Investors Holdings Manager LLC.

    Upon the completion of the Restructuring (as defined in Item 4 herein), each of Stonepeak GP Investors Holdings LP, Stonepeak GP Investors Upper Holdings LP, and Stonepeak GP Investors Holdings Manager LLC may be deemed to indirectly exercise voting and dispositive power over the Common Stock and Warrants held directly by Stonepeak Magnet, and have been added as Reporting Persons to the Schedule 13D.  Also upon completion of the Restructuring, Stonepeak GP Investors Manager LLC no longer may be deemed to indirectly exercise voting and dispositive power over the Common Stock and Warrants held directly by Stonepeak Magnet, and so has been removed as a Reporting Person from the Schedule 13D.

    The principal business address of each Reporting Person is 55 Hudson Yards, 550 W. 34th Street, 48th Floor, New York, New York 10001.

    The agreement among each of the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Exchange Act is attached hereto as Exhibit 9.

    (d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.


     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 10 of 13 Pages
    Item 3.
    Source and Amount of Funds or Other Consideration

    Item 3 of the Original Schedule 13D is hereby amended by adding the following:

    The response to Item 4 of this Schedule 13D is incorporated by reference herein.

    Item 4.
    Purpose of Transaction

    Item 4 of the Original Schedule 13D is hereby amended by adding the following:

    On June 26, 2023, the Reporting Persons completed an internal restructuring (the “Restructuring”), pursuant to which Stonepeak GP Investors Holdings LP, Stonepeak GP Investors Upper Holdings LP, and Stonepeak GP Investors Holdings Manager LLC were created and Stonepeak GP Investors Holdings LP replaced Stonepeak GP Investors Manager LLC as the managing member of Stonepeak GP Investors IV LLC.  Following the Restructuring, Stonepeak GP Investors Manager LLC ceased being a beneficial owner of any shares of Common Stock.

    In connection with their regular review of their investment in the Issuer, and based on current market conditions and other factors, the Reporting Persons are currently evaluating alternatives for their current investment and potential future investment in the Issuer, including but not limited to restructuring the terms of the Issuer’s existing debt instruments, a potential divestiture of certain assets, a potential sale of the Issuer, another form of extraordinary corporate transaction or other possible transactions. Towards that end, the Reporting Persons have engaged in and/or may engage in communications with, among others, members of the Issuer’s management, members of the Issuer’s board of directors, shareholders and/or debtholders of the Issuer, legal, financial, regulatory, technical, industry or other advisors, potential sources of financing, or other persons, regarding, among other things, the review and evaluation of strategic alternatives, opportunities to increase shareholder value, Issuer operations, governance and control, and other matters related to the Issuer or the Reporting Persons’ investment in the Issuer. In connection with such communications, the Reporting Persons may seek to enter into a non-disclosure agreement.

    Item 5.
    Interest in Securities of the Issuer

    Item 5 of the Original Schedule 13D is hereby amended by adding the following:

    (a) As of the date hereof, each of the Reporting Persons may be deemed the beneficial owner of 20,614,093 shares of Common Stock, which represents approximately 19.2% of the outstanding shares of Common Stock.  This amount includes: (i) 3,500,000 shares of Common Stock held directly by Stonepeak Magnet; and (ii) 17,114,093 shares of Common Stock that the Reporting Persons currently have the right to acquire upon exercise of the Warrants held directly by Stonepeak Magnet.

    The foregoing beneficial ownership percentage is based on the sum of (i) 90,498,491 shares of Common Stock outstanding as of May 8, 2023, based on the Issuer’s quarterly report on Form 10-Q, filed with the SEC on May 10, 2023, plus, (ii) for purposes of calculating the Reporting Person’s beneficial ownership pursuant to Rule 13d-3(d)(i) under the Act, the 17,114,093 shares of Common Stock issuable upon exercise of the Warrants, for a total of 107,612,584 shares of Common Stock outstanding.

    (b) The Reporting Persons have shared voting power and shared dispositive power with regard to the 3,500,000 shares of Common Stock held directly by Stonepeak Magnet and the 17,114,093 shares of Common Stock that the Reporting Persons currently have the right to acquire upon exercise of the Warrants held directly by Stonepeak Magnet.

    (d) The response to Item 4 of this Amendment No. 1 is incorporated by reference herein. Certain investors in the Reporting Persons may have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock that may be deemed to be beneficially owned by the Reporting Persons.

    (e) This Item 5(e) is not applicable.

    Item 6.
    Contracts, Arrangements, Undertakings or Relationships with Respect to Securities of the Issuer

    Item 6 of the Original Schedule 13D is hereby amended by adding the following:

    The response to Item 4 of this Amendment No. 1 is incorporated by reference herein.


     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 11 of 13 Pages
    Item 7.
    Material to Be Filed as Exhibits

    Item 7 of the Original Schedule 13D is hereby amended by adding the following:

    Exhibit 9 – Joint Filing Agreement


     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 12 of 13 Pages
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    STONEPEAK MAGNET HOLDINGS LP
     
    By:
    Stonepeak Associates IV LLC, its sole general partner
     
    By:
    Stonepeak GP Investors IV LLC, its sole member
     
    By:
    Stonepeak GP Investors Holdings LP, its managing member
     
    By:
    Stonepeak GP Investors Upper Holdings LP, its general partner
     
    By:
    Stonepeak GP Investors Holdings Manager LLC, its general partner
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    STONEPEAK ASSOCIATES IV LLC
     
    By:
    Stonepeak GP Investors IV LLC, its sole member
     
    By:
    Stonepeak GP Investors Holdings LP, its managing member
     
    By:
    Stonepeak GP Investors Upper Holdings LP, its general partner
     
    By:
    Stonepeak GP Investors Holdings Manager LLC, its general partner
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    STONEPEAK GP INVESTORS IV LLC
     
    By:
    Stonepeak GP Investors Holdings LP, its managing member
     
    By:
    Stonepeak GP Investors Upper Holdings LP, its general partner
     
    By:
    Stonepeak GP Investors Holdings Manager LLC, its general partner
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    STONEPEAK GP INVESTORS HOLDINGS LP
     
    By:
    Stonepeak GP Investors Upper Holdings LP, its general partner
     
    By:
    Stonepeak GP Investors Holdings Manager LLC, its general partner
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    STONEPEAK GP INVESTORS UPPER HOLDINGS LP
     
    By:
    Stonepeak GP Investors Holdings Manager LLC, its general partner
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    STONEPEAK GP INVESTORS HOLDINGS MANAGER LLC
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    MICHAEL DORRELL
     
    By:
    /s/ Michael Dorrell
         
    July 6, 2023
       

    Attention: Intentional misstatements or omissions of act constitute federal violations (see 18 U.S.C. 1001).


     
    SCHEDULE 13D
     
    CUSIP No.: 01021X100
     
    Page 13 of 13 Pages
    Exhibit 9

    JOINT FILING AGREEMENT
    The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of Akumin, Inc., dated as of July 6, 2023, is, and any amendments thereto (including amendments on Schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.

     
    STONEPEAK MAGNET HOLDINGS LP
     
    By:
    Stonepeak Associates IV LLC, its sole general partner
     
    By:
    Stonepeak GP Investors IV LLC, its sole member
     
    By:
    Stonepeak GP Investors Holdings LP, its managing member
     
    By:
    Stonepeak GP Investors Upper Holdings LP, its general partner
     
    By:
    Stonepeak GP Investors Holdings Manager LLC, its general partner
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    STONEPEAK ASSOCIATES IV LLC
     
    By:
    Stonepeak GP Investors IV LLC, its sole member
     
    By:
    Stonepeak GP Investors Holdings LP, its managing member
     
    By:
    Stonepeak GP Investors Upper Holdings LP, its general partner
     
    By:
    Stonepeak GP Investors Holdings Manager LLC, its general partner
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    STONEPEAK GP INVESTORS IV LLC
     
    By:
    Stonepeak GP Investors Holdings LP, its managing member
     
    By:
    Stonepeak GP Investors Upper Holdings LP, its general partner
     
    By:
    Stonepeak GP Investors Holdings Manager LLC, its general partner
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    STONEPEAK GP INVESTORS HOLDINGS LP
     
    By:
    Stonepeak GP Investors Upper Holdings LP, its general partner
     
    By:
    Stonepeak GP Investors Holdings Manager LLC, its general partner
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    STONEPEAK GP INVESTORS UPPER HOLDINGS LP
     
    By:
    Stonepeak GP Investors Holdings Manager LLC, its general partner
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    STONEPEAK GP INVESTORS HOLDINGS MANAGER LLC
     
    By:
    /s/ Michael Dorrell
     
    Name: Michael Dorrell
     
    Title: Chairman, Chief Executive Officer and Co-Founder
         
     
    MICHAEL DORRELL
     
    By:
    /s/ Michael Dorrell
         
    July 6, 2023
       



    Get the next $AKU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKU

    DatePrice TargetRatingAnalyst
    11/14/2022$3.50 → $3.00Buy → Speculative Buy
    Canaccord Genuity
    More analyst ratings

    $AKU
    Financials

    Live finance-specific insights

    See more
    • Akumin Inc. Provides Update on its Restructuring Transaction

      /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

      1/31/24 10:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Announces Second Quarter 2023 Results, Revised FY23 Financial Outlook and Establishment of Special Committee

      PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company"), a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service-line needs, announced today its financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Akumin delivered second quarter same-store volume performance on a consolidated basis as follows:+3.1% for MRI+16.5% for PET/CT+3.4% for Oncology Patient StartsThe Company reported revenue totaling $184.8 million for the second quarter, a $7.3 million or 4% decrease over the second quarter of last year.

      8/9/23 5:23:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin to Host Second Quarter 2023 Financial Results Call on August 10, 2023

      PLANTATION, Fla., Aug. 8, 2023 /PRNewswire/ - Akumin Inc. (TSX:AKU) ("Akumin" or the "Company") will host a conference call at 8:30 a.m. Eastern Time, Thursday, August 10, 2023, to discuss its second quarter 2023 financial results.  The financial results are expected to be available on Wednesday, August 9, 2023. To access the conference call, participants may join by using an appropriate dial-in number available through https://akum.in/Q2-2023-Results-Dial-In-Numbers or via webcast at https://akum.in/Q2-2023-Results-Webcast. A related presentation will be available from Akumin's website (www.akumin.com). Participants are asked to connect at least 10 minutes prior to the beginning of the call

      8/8/23 5:23:00 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akumin downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Akumin from Buy to Speculative Buy and set a new price target of $3.00 from $3.50 previously

      11/14/22 8:59:34 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

      SC 13G/A - AKUMIN INC. (0001776197) (Subject)

      2/12/24 4:37:41 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Akumin Inc.

      SC 13G - AKUMIN INC. (0001776197) (Subject)

      2/12/24 4:31:27 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

      SC 13G/A - AKUMIN INC. (0001776197) (Subject)

      2/7/24 10:43:55 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Foursixthree Capital Lp claimed ownership of 10,556,851 shares (SEC Form 3)

      3 - AKUMIN INC. (0001776197) (Issuer)

      2/5/24 4:50:02 PM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Bienias Ronald J.

      3 - AKUMIN INC. (0001776197) (Issuer)

      10/26/23 10:40:46 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Kumar Krishna

      4 - AKUMIN INC. (0001776197) (Issuer)

      7/18/23 1:31:57 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akumin Announces Changes to Leadership Team

      Krishna Kumar, Current President & Chief Operating Officer, Appointed Chief Executive Officer Chandra Westergaard Named General Counsel PLANTATION, Fla., Feb. 8, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") announced today that Krishna Kumar, who has served as President and Chief Operating Officer at the Company, has been appointed Chief Executive Officer, effective immediately. He succeeds Riadh Zine, Akumin's Founder, who is stepping down as Chairman and Chief Executive Officer. Akumin also announced that Chandra Westergaard has been named General Counsel and will oversee the Company's legal and compliance functions. "On behalf of Akumin, I would like to thank Riadh for his dedica

      2/8/24 5:00:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Inc. Completes Deleveraging Transaction, Becomes a Private Company Wholly-Owned by Stonepeak

      Akumin well-positioned to continue providing top-quality radiology and oncology services to patients, health systems, hospitals, and physician groups across the U.S. PLANTATION, Fla., Feb. 6, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") today announced that it has completed its deleveraging transaction, becoming a private company wholly-owned by Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets. The deleveraging and recapitalization transaction was implemented through a voluntary, court-supervised financial restructuring process, which is now complete. "We are pleased to have concluded this process and are excited to enter our next chapt

      2/6/24 6:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Inc. Provides Update on its Restructuring Transaction

      /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

      1/31/24 10:26:00 PM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    SEC Filings

    See more
    • SEC Form EFFECT filed by Akumin Inc.

      EFFECT - AKUMIN INC. (0001776197) (Filer)

      2/13/24 12:15:09 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form 15-12G filed by Akumin Inc.

      15-12G - AKUMIN INC. (0001776197) (Filer)

      2/7/24 6:11:57 AM ET
      $AKU
      Medical Specialities
      Health Care
    • SEC Form S-8 POS filed by Akumin Inc.

      S-8 POS - AKUMIN INC. (0001776197) (Filer)

      2/7/24 6:09:57 AM ET
      $AKU
      Medical Specialities
      Health Care

    $AKU
    Leadership Updates

    Live Leadership Updates

    See more
    • AKUMIN ANNOUNCES LEADERSHIP TRANSITION

      PLANTATION, Fla., Dec. 29, 2023 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its Board of Directors has appointed Ronald J. Bienias, Akumin's Chief Restructuring Officer and Partner and Managing Director of AlixPartners, LLP, as Interim Chief Financial Officer, effective today. He will also maintain his current role as Chief Restructuring Officer. Ronald's appointment follows the resignation of David Kretschmer, as Akumin's Chief Financial Officer effective today. Ronald has more than 20 years of experience serving in interim leadership roles or as an advisor at both large and

      12/29/23 7:52:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin Announces Change of Auditor

      PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) announced today that it has changed its auditor from Ernst & Young LLP ("EY") to Deloitte & Touche LLP ("Deloitte"). Effective as of August 9, 2023, the audit committee (the "Audit Committee") of the board of directors (the "Board") of the Company dismissed EY as the Company's independent registered public accounting firm. EY audited the Company's financial statements for each of the past two fiscal years ended December 31, 2022 and 2021, and EY's reports did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or

      8/9/23 5:31:00 PM ET
      $AKU
      Medical Specialities
      Health Care
    • Akumin appoints President and Chief Operating Officer

      PLANTATION, Fla., June 12, 2023 /CNW/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) today announced the appointment of Krishna Kumar as President and Chief Operating Officer of the Company, effective as of June 16, 2023. Krishna has valuable experience and exceptional insight into the radiology space, having served as Senior Vice President & Business Leader - Precision Diagnosis at Philips North America, where he built a top performing team and business, over the last four years. Prior to this role, he led global businesses in Pathology, Oncology and Neuro at Philips based in Amsterdam, Netherlands from 2015-2019 and prior thereto was the CEO of Philips India. Before joini

      6/12/23 6:59:57 AM ET
      $AKU
      Medical Specialities
      Health Care